MRK - Elanco Animal Health To Offload Aqua Business For $1.3B Plans To Lower Debt Burden | Benzinga
Merck Animal Health, a division of Merck & Co Inc (NYSE:MRK), has agreed to acquire Elanco Animal Health Incorporated’s aqua business (NYSE:ELAN) for $1.3 billion in cash.
The business consists of a portfolio of medicines and vaccines, nutrition, and supplements for aquatic species; two related aqua manufacturing facilities in Canada and Vietnam; and a research facility in Chile.
The acquisition is expected to be completed by mid-year 2024.
Upon closing, the acquisition will broaden Merck Animal Health’s aqua portfolio with products such as CLYNAV, a new generation DNA-based vaccine that protects Atlantic salmon against ...